Non-Small Cell Lung Cancer (NSCLC) Therapeutic Pipeline Assessment, 2022 | Insights Into the Emerging Therapies, Clinical and Non-Clinical Trials, Treatment Algorithm | Key Companies Covered - Regeneron, Immutep, Imjudo, AstraZeneca

As per DelveInsight's assessment, globally, about 135+ key pharma and biotech companies are working on 150+ pipeline drugs in the Non-Small-Cell Lung cancer (NSCLC) therapeutics landscape based on different Routes of Administration (RoA), Mechanism of Action (MoA), and molecule types. Several of the therapies are in the advanced stages of clinical development and are expected to launch in the coming years.

"Non-Small-Cell Lung cancer (NSCLC) Pipeline Insight, 2022" report by DelveInsight provides a comprehensive analysis of the ongoing clinical development activities and growth prospects across the Non-Small Cell Lung Cancer Therapeutics Market.

The report provides a detailed description of the drug, including the mechanism of action, type, stage, route of administration, molecule type, clinical studies, inactive pipeline products, and NDA approvals (if any).

The report also covers commercial and clinical activities of the pipeline products from the pre-clinical developmental phase to the marketed stage. Additionally, it presents the ongoing developments in the therapeutics segment, including collaborations, licensing, mergers & acquisitions (M&A), funding, designations, and other product-related details.

Non-Small-Cell Lung cancer (NSCLC) Pipeline Analysis
The report provides insights into:
• The report provides detailed insights into the key companies that are developing therapies in the Non-Small Cell Lung Cancer Market.
• The report also evaluates different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for Non-Small Cell Lung Cancer treatment.
• It analyzes the key companies involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.
• It navigates the emerging drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type.
• Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement, and financing details for future advancement of the Non-Small Cell Lung Cancer market.

The report is built using data and information traced from the researcher's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations, and featured press releases from company/university websites and industry-specific third-party sources, etc.

Request for Sample PDF to Understand More About the Treatment Outlook and Future Perspectives:
https://www.delveinsight.com/report-store/non-small-cell-lung-cancer-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=rpr

DelveInsight's Report covers around 150+ products under different phases of clinical development like -
• Late-stage products (Phase III)
• Mid-stage products (Phase II)
• Early-stage products (Phase I)
• Pre-clinical and discovery stage candidates
• Discontinued & Inactive candidates

Non-Small-Cell Lung cancer (NSCLC) Therapeutics Analysis
There are approx. 135+ key companies developing therapies for Non-Small-Cell Lung cancer (NSCLC). Currently, Daiichi Sankyo has its Non-Small-Cell Lung cancer (NSCLC) drug candidates in the most advanced stage of clinical development.

Key Companies in the Non-Small Cell Lung Cancer (NSCLC) Therapeutics Market include:
BridgeBio Pharma, Daiichi Sankyo, EMD Serono/Merck, BridgeBio Pharma, Abbvie/Pfizer, Eli Lilly and Company, BioNTech SE, Shenzhen TargetRx, Taiho Pharmaceutical, Chong Kun Dang, Bristol Myers Squibb, Innovent Biologics, Xuanzhu Biopharmaceutical, GeneScience Pharmaceuticals, InventisBio, Apollomics, Imugene, Ono Pharmaceutical/Pierre Fabre, Jiangsu Hengrui Medicine Co., Bristol-Myers Squibb, Surface Oncology, Inhibrx, Sinocelltech, Mirati Therapeutics, REVOLUTION Medicines, Yong Shun Technology Development, Iovance Biotherapeutics, Galecto Biotech, and many others.

Non-Small-Cell Lung cancer (NSCLC) Drugs covered in the report include:
• Datopotamab deruxtecan: Daiichi Sankyo
• JDQ443: Novartis
• MRTX849: Mirati Therapeutics
• INBRX-106: Inhibrx
And many others

Download Sample Pages to Get an in-depth Assessment of the Emerging Therapies and Key Companies:
https://www.delveinsight.com/sample-request/non-small-cell-lung-cancer-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=rpr

Table of Content
1. Report Introduction
2. Executive Summary
3. Non-Small Cell Lung Cancer Current Treatment Patterns
4. Non-Small Cell Lung Cancer - DelveInsight's Analytical Perspective
5. Therapeutic Assessment
6. Non-Small Cell Lung Cancer Late Stage Products (Phase-III)
7. Non-Small Cell Lung Cancer Mid-Stage Products (Phase-II)
8. Early Stage Products (Phase-I)
9. Pre-clinical Products and Discovery Stage Products
10. Inactive Products
11. Dormant Products
12. Non-Small Cell Lung Cancer Discontinued Products
13. Non-Small Cell Lung Cancer Product Profiles
14. Non-Small Cell Lung Cancer Key Companies
15. Non-Small Cell Lung Cancer Key Products
16. Dormant and Discontinued Products
17. Non-Small Cell Lung Cancer Unmet Needs
18. Non-Small Cell Lung Cancer Future Perspectives
19. Non-Small Cell Lung Cancer Analyst Review
20. Appendix
21. Report Methodology
*The table of contents is not exhaustive; the final content may vary.

Request the Sample PDF to Get Detailed Insights About the Reports Offerings:
https://www.delveinsight.com/sample-request/non-small-cell-lung-cancer-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=rpr

Contact Info:
Shruti Thakur
Manager - Marketing & International Branding
Email: info@delveinsight.com
Request for Sample Copy of the Report at:
https://www.delveinsight.com/sample-request/non-small-cell-lung-cancer-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=rpr

428, D21 Corporate Park, Sector-21, Dwarka, New Delhi-110077, India

About DelveInsight
DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance.

This release was published on openPR.